Ardea reports additional positive results from Phase IIa study of gout drug - Trading Markets (press release)

Ardea reports additional positive results from Phase IIa study of gout drug Trading Markets (press release) In particular, no renal toxicity was noted in clinical chemistry, gross pathology or histopathology at doses up to 300mg/kg/day, said Ardea. ... and more »

Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study ... - Reuters

Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study ... Reuters In particular, no renal toxicity was noted in clinical chemistry, gross pathology or histopathology at doses up to 300 mg/kg/day. "RDEA594 continues to move ...